Dow Down0.11% Nasdaq Up0.23%

Immunomedics Inc. (IMMU)

3.40 Up 0.07(2.01%) 2:06PM EDT - Nasdaq Real Time Price
ProfileGet Profile for:
Immunomedics Inc.
300 The American Road
Morris Plains, NJ 07950
United States - Map
Phone: 973-605-8200
Fax: 973-605-8282

Index Membership:N/A
Full Time Employees:119

Business Summary 

Immunomedics, Inc., a biopharmaceutical company, focuses on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune, and other serious diseases. Its products include epratuzumab, which is in two Phase III clinical trials for the treatment of lupus; Yttrium-90 labeled clivatuzumab tetraxetan, a therapeutic product candidate that completed a Phase Ib clinical trial for the treatment of pancreatic cancer; and Veltuzumab, a humanized anti-CD20 monoclonal antibody for the treatment of non-Hodgkin lymphoma (NHL). The company’s products also comprise Milatuzumab, a transmembrane protein that is highly expressed in MM and other B-cell lymphomas and leukemias, and in certain solid tumors; Yttrium-90-Labeled Epratuzumab Tetraxetan, a radiolabeled CD22 antibody product candidate for patients with NHL; Labetuzumab, a proprietary humanized antibody, which is in Phase II clinical development stage, targets the carcinoembryonic antigen, CEACAM5; and hRS7, an internalizing humanized anti-epithelial glycoprotein-1 antibody. It also manufactures and commercializes LeukoScan, a diagnostic imaging system to determine the location and extent of infection/inflammation in bone in patients with suspected osteomyelitis, including patients with diabetic foot ulcers. The company has strategic partnerships and relationships with UCB, S.A.; and a collaboration agreement with Algeta ASA for the development of epratuzumab. Immunomedics, Inc. was founded in 1982 and is headquartered in Morris Plains, New Jersey.

Key Statistics

Company Websites 
Home Page
Search Yahoo! for:
More on Immunomedics Inc.

Corporate Governance 
Immunomedics Inc.’s ISS Governance QuickScore as of Aug 1, 2014 is 3. The pillar scores are Audit: 1; Board: 9; Shareholder Rights: 1; Compensation: 5.
Brought to you by Institutional Shareholder Services (ISS)

Key Executives 
Dr. David M. Goldenberg , 76
Founder, Chairman, Chief Medical Officer, Chief Scientific Officer and Director of IBC Pharmaceuticals Inc
Ms. Cynthia L. Sullivan , 59
Chief Exec. Officer, Pres, Director and Pres of Ibc Pharmaceuticals Inc
Mr. Gerard G. Gorman , 63
Mr. Peter Pfreundschuh , 45
Chief Financial Officer and VP of Fin.
Dr. Chau Cheng ,
Sr. Director of Investor Relations & Grant Management
Amounts are as of Dec 31, 2013 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
Currency in USD.
View Insiders